Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873949 | 1.00 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL2021416 | 1.00 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5462678 | 0.97 | ADH1B (0.39) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6766085 | 0.97 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL9697171 | 0.90 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL866538 | 0.83 | CYP1A2 (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4680720 | 0.83 | SIGMAR1 (0.39) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL868167 | 0.83 | CYP1A2 (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL867094 | 0.83 | CYP1A2 (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL866853 | 0.83 | CYP1A2 (0.42) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569928-A4 | THERAPEUTIC COMPOUNDS AND METHODS | GOVERNMENT OF THE STATE OF SAR (MY) | 2008-12-10 | — | — | EP | claimed |
| JP-2006508098-A | — | — | 2006-03-09 | — | — | JP | claimed |
| EP-1569928-A1 | THERAPEUTIC COMPOUNDS AND METHODS | The Government of the State of Sarawak, Malaysia (MY) | 2005-09-07 | — | — | EP | claimed |
| WO-2004041812-A1 | THERAPEUTIC COMPOUNDS AND METHODS | THE GOVERNMENT OF THE STATE OF SARAWAK, MALAYSIA (MY) | 2004-05-21 | — | — | WO | claimed |
| US-20030181514-A1 | Therapeutic compounds and methods | GOVERNMENT OF THE STATE OF SARAWAK, MALAYSIA (MY) | 2003-09-25 | — | — | US | claimed |
| WO-2023163082-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE BATTERY COMPRISING SAID NONAQUEOUS ELECTROLYTE SOLUTION, AND COMPOUND | ＭＵアイオニックソリューションズ株式会社 | 2023-08-31 | — | — | WO | disclosed |
| US-11635685-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20220026803-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20210149300-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-2099456-A2 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | Progenics Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070462-A2 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-0111711-A2 | Heterocyclically substituted hydroxyalkyl-azolyl derivatives | BAYER AG (DE) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181514-A1 | Therapeutic compounds and methods | DHFR, CPT1A, NDUFAB1 | ADH1B 391/4885ADH1C 2420/4885ADH1A 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.